Navigation Links
FDA Accepts Zingo(TM) Supplemental New Drug Application to Reduce Pain Associated With Peripheral Needle Insertion Procedures in Adults
Date:5/21/2008

this press release include matters that involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to differ materially from results expressed or implied by this press release. Such risk factors include, among others: whether Zingo gains FDA approval in the adult indication, and the degree to which Zingo gains market acceptance. Actual results may differ materially from those contained in the forward-looking statements in this press release. Additional information concerning these and other risk factors is contained in Anesiva's annual report on Form 10-K for the year ended December 31, 2007, and its most recent filing on Form 10-Q.

(1) Data on file at Anesiva, Inc.


'/>"/>
SOURCE Anesiva, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. FDA Accepts ISO-Vorin(TM) New Drug Application Amendment Submitted by Spectrum Pharmaceuticals
2. FDA Accepts Sucampos sNDA for Lubiprostone (8 mcg) for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C)
3. FDA Accepts Ranexa(R) sNDA and NDA for Filing
4. EMEA Accepts for Review Vidaza(R) Marketing Authorization Application for Higher-Risk Myelodysplastic Syndromes
5. Imaging Diagnostic Systems Accepts Resignations of Outside Directors
6. U.S. Government Accepts $192 Million of sanofi pasteur H5N1 Bulk Vaccine Antigen for Pandemic Stockpile
7. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
8. Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program
9. Anesiva Signs Co-Promotion and Distribution Agreement With Sagent Pharmaceuticals for Zingo(TM) in U.S. Hospitals
10. Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM)
11. Anesiva Announces Submission of Supplemental New Drug Application for Zingo(TM) to Reduce Pain Associated With Needle Insertion Procedures in Adults
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... KEEGO HARBOR, Mich. , Sept. 18, 2014  Health ... -based biotech firm investigating early-stage algae bioactive compounds and metabolic ... member to the company,s board of directors. Ms. Nola ... executive and investment advisor joined the board effective September 17, ... have Ms. Masterson agree to join our board," states ...
(Date:9/18/2014)... -- Research and Markets has announced the ... Industry Report, 2014-2017" report to their offering. ... can differentiate into specialized cells and can divide (through ... can be applied to treatment of cardiovascular diseases, leukemia ... damage or lesion of liver, kidney and other parenchymal ...
(Date:9/18/2014)... Lewisville, TX (PRWEB) September 18, 2014 ... PVC-C, a FM-4910 listed material, to stay competitive ... industries. These high-performance materials ultimately impact product ... company’s President and owner. , Established in 1980 ... held strong as many fabricators have left the ...
(Date:9/18/2014)... , Sept. 18, 2014 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ... previously announced concurrent but separate underwritten offerings of 10,000,000 ... the public of $2.00 per share, for expected gross ... Series A Convertible Preferred Stock at a price to ... proceeds of $20 million. Each share of Series A ...
Breaking Biology Technology:Health Enhancement Announces New Board Member In Advance Of Annual Shareholder Meeting 2Global and Chinese Stem Cell Industry Report, 2014-2017 2Global and Chinese Stem Cell Industry Report, 2014-2017 3Leatherwood Plastics Selects Vycom’s Flametec PVC-C Material to Stay Competitive in Semiconductor and Lab Equipment Industries 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 3
... of revenue growth ... 2007 Highlights: * Product ... SET pulse oximeter units increase 20% to 116,300 units, IRVINE, Calif., Feb. ... Measure-Through,Motion & Low Perfusion pulse oximetry, today announced its financial,results for both the ...
... Replidyne, Inc.,(Nasdaq: RDYN ) today announced its financial results ... Replidyne reported a net loss of $16.9 million for ... per basic and diluted common share,of $0.63 per share, compared ... and diluted common share, for the quarter ended December 31, ...
... Market Research,a global provider of pharmaceutical competitive intelligence ... critical strategic insight,for pharma and biotech companies with ... therapies., In this report, entitled MedPredict Thought ... global Thought Leader Panel,debates tough questions facing drug ...
Cached Biology Technology:Masimo Reports Fourth Quarter 2007 and Full Year 2007 Financial Results 2Masimo Reports Fourth Quarter 2007 and Full Year 2007 Financial Results 3Masimo Reports Fourth Quarter 2007 and Full Year 2007 Financial Results 4Masimo Reports Fourth Quarter 2007 and Full Year 2007 Financial Results 5Masimo Reports Fourth Quarter 2007 and Full Year 2007 Financial Results 6Masimo Reports Fourth Quarter 2007 and Full Year 2007 Financial Results 7Masimo Reports Fourth Quarter 2007 and Full Year 2007 Financial Results 8Masimo Reports Fourth Quarter 2007 and Full Year 2007 Financial Results 9Masimo Reports Fourth Quarter 2007 and Full Year 2007 Financial Results 10Masimo Reports Fourth Quarter 2007 and Full Year 2007 Financial Results 11Masimo Reports Fourth Quarter 2007 and Full Year 2007 Financial Results 12Replidyne Announces 2007 Fourth Quarter and Full Year Results 2Replidyne Announces 2007 Fourth Quarter and Full Year Results 3Replidyne Announces 2007 Fourth Quarter and Full Year Results 4Replidyne Announces 2007 Fourth Quarter and Full Year Results 5Replidyne Announces 2007 Fourth Quarter and Full Year Results 6Replidyne Announces 2007 Fourth Quarter and Full Year Results 7Unmet Needs Provide Challenges and Opportunities for Rheumatoid Arthritis Drug Developers According to MedPredict Report 2
(Date:9/18/2014)... icy moon of Uranus, is one of the most ... Despite its relatively small size, Miranda appears to have ... the formation of at least three remarkable and unique ... These coronae are visible in Miranda,s southern hemisphere, and ... corona, the largest, has ridges and troughs with up ...
(Date:9/18/2014)... University and the Quebec government have discovered microplastics ... Journal of Fisheries and Aquatic Sciences . , ... or industrial cleansers, to which they are commonly ... and buoyancy, they may readily pass through sewage ... in the world,s oceans, but have only recently ...
(Date:9/18/2014)... The fall foliage season that prompts millions of Americans to ... later and possibly last a little longer within a century, ... leaf peeping in some areas of the United States as ... report in the journal Global Ecology and Biogeography . ... that is the state tree of New Hampshire could ...
Breaking Biology News(10 mins):Miranda: An icy moon deformed by tidal heating 2Miranda: An icy moon deformed by tidal heating 3Miranda: An icy moon deformed by tidal heating 4Miranda: An icy moon deformed by tidal heating 5Miranda: An icy moon deformed by tidal heating 6Miranda: An icy moon deformed by tidal heating 7Microplastic pollution discovered in St. Lawrence River sediments 2Fall foliage season may be later, but longer on warmer Earth 2Fall foliage season may be later, but longer on warmer Earth 3Fall foliage season may be later, but longer on warmer Earth 4
... the laboratory of Assistant Professor Frank J. Slack at Yale ... is regulated in lung cancer, presenting new possibilities for diagnosis ... the journals Cell and Developmental Cell. , The oncogene Ras ... where it is over-expressed or activated by mutation. According to ...
... prevented allergic reactions in laboratory mice, as well as ... California, Los Angeles (UCLA) researchers report in the April ... future, the investigators say, these promising results could lead ... allergies, but also possibly for severe food allergies such ...
... dead bone of a transplanted skeletal graft into living tissue ... therapy to stimulate the body into treating the foreign splint ... of cancer and trauma patients each year who suffer with ... Feb. 13 and will appear in the March 1 issue ...
Cached Biology News:Yale Scientists Find MicroRNA Regulates Ras Cancer Gene 2Novel Therapy Tested in Mice Could Chase Away Cat Allergies 2Novel Therapy Tested in Mice Could Chase Away Cat Allergies 3Gene therapy converts dead bone graft to new, living tissue 2Gene therapy converts dead bone graft to new, living tissue 3Gene therapy converts dead bone graft to new, living tissue 4
... The Fluorescence Test Plate consists of ... format, with Inert Organic Fluorescent Compounds embedded ... be used on BioTeks FLx800 and Synergy ... ideal for GLP compliance while reducing the ...
... Feature Extraction Software reads and ... to prepare microarray data for ... * one 2-year license ... NFP/Academic accounts , * ...
... Stain combo offers these benefits: ... Offers a safer and ... Eliminates risks to yourself, the environment and your ... bp to >30 kb. UltraPure Agarose is a standard ...
Anti-WT-1 Liquid. In 10 μM PBS, 0.2 % BSA, pH 7.6. Recognizes the ~47-55 kDa Wilm's tumor protein in Wilm's tumor tissue. ...
Biology Products: